MYLS22

Opa1 inhibitor MYLS22 can result in higher maximal and residual cytoplasmic calcium levels, and alter T cell receptor (TCR) signaling in thymocytes with higher susceptibility to apoptosis.^{<a class="sref" href="#s_ref">[2]</a>}

MYLS22, a small molecule first-in-kind Opa1-specific inhibitor, can affect angiogenesis, tumor growth and metastasis by impinging on NF-κB activity and on angiogenic gene expression.^{<a class="sref" href="#s_ref">[1]</a>}

• Cell lines

  Jurkat cells

• Concentrations

  50 μM

• Incubation Time

  2 h

• Method

  Jurkat cells are cultured in 1640 media supplemented with 10% FCS, 4 mM L-glutamine, 1 penicillin/streptomycin, and 55 μM β-mercaptoethanol under 5% CO2, atmospheric oxygen, at 37 °C in a humidified incubator. For MYLS22 treatment, cells are ished and resuspended in RPMI supplemented with 2% FCS and 50 μM MYLS22 for 2 h before the experiment is started.The treated cells are used for Calcium measurements, Flow cytometry, Electron microscopy, and Western blotting.

• Animal Models

  C57BL6/J mice(Opa1+/ΔEC, Opa1iΔEC, Opa1+/iΔEC, Opa1+/ΔEC, Mfn1iΔEC)

• Dosages

  10 mg/kg

• Administration

  i.p.